What Happened?
New Haven, CT-based Arvinas Appointed Manny Litchman as Chief Executive Officer.
About the Company
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
About the Person
Manny is the President and CEO of Arvinas Inc. Previously, he was Senior Vice President and Global Program Head at Novartis Pharmaceuticals for the CTL019 project – a collaboration with the University of Pennsylvania (Penn) involving personalized cell and gene therapy. Manny started his pharmaceutical career in Oncology Clinical Research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he held positions of increasing responsibility in Oncology Development. From 2000 – 2001 he was Senior Equity Analyst at Ursus Capital, a biotechnology hedge fund. He then returned to Novartis, where he was Head of Oncology Business Development & Licensing until execution of the Penn deal in 2012. Manny obtained his BA in German Literature from Princeton University and his MD from Yale University School of Medicine. He completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital / Weill Cornell Medical Center.
Info Source
Press Release
Short Profile